Setting

Asia Pacific Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity

Published: 28 Sep 2020 | Report Code: 10247704 | Pages: 122

Asia Pacific pharmacogenomics market will grow by 10.3% annually with a total addressable market cap of $21.7 billion over 2020-2030 owing to the rising adoption of personalized medicine and usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic. Highlighted with 35 tables and 49 figures, this 122-page report “Asia Pacific Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmacogenomics market in every aspect of the classification from perspectives of Service, Technology, Application, End User, and Country. Based on Service, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Genotyping • SNP Identification • Diagnostics • Other Services Based on Technology, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Polymerase Chain Reaction (PCR) • Microarray • Sequencing • Electrophoresis • Mass Spectrometry • Other Technologies Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oncology • Infectious Diseases • Neurology/Psychiatry • Cardiovascular • Pain Management • Other Applications Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Hospitals and Clinics • Pharmaceutical Companies • Research Institutes Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) Detailed analysis and annual revenue 2019-2030 are available for each key national market. The breakdown of key national markets by Service, Technology, and Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific pharmacogenomics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): 23andMe, Inc. Abbott Laboratories Admera Health, LLC Agena Biosciences, Inc. Astra Zeneca PLC Bayer AG Becton, Dickinson and Company Cancer Genetics, Inc. Dynamic DNA Laboratories Empire Genomics LLC F. Hoffmann-La Roche Ltd geneOmbio Technologies Pvt Ltd. Genomic Health, Inc. Illumina, Inc. Laboratory Corporation of America Holdings Myriad Genetics Inc. Oneome LLC Opko Health, Inc. Pathway Genomics Corporation QIAGEN N.V. Quest Diagnostics Incorporated Teva Pharmaceuticals Industries Ltd. Thermo Fisher Scientific Inc. Transgenomic, Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	6
1.1 Industry Definition and Research Scope	6
1.1.1 Industry Definition	6
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	14
1.2.6 Market Size/Share Estimation	15
1.2.7 Research Limitations	16
1.3 Executive Summary	17
2 Market Overview and Dynamics	20
2.1 Market Size and Forecast	20
2.1.1 Impact of COVID-19 on the Market	24
2.2 Major Growth Drivers	26
2.3 Market Restraints and Challenges	30
2.4 Emerging Opportunities and Market Trends	33
2.5 Porter’s Fiver Forces Analysis	37
3 Segmentation of Asia Pacific Market by Service	41
3.1 Market Overview by Service	41
3.2 Genotyping	43
3.3 SNP Identification	44
3.4 Diagnostics	45
3.5 Other Services	47
4 Segmentation of Asia Pacific Market by Technology	48
4.1 Market Overview by Technology	48
4.2 Polymerase Chain Reaction (PCR)	50
4.3 Microarray	51
4.4 Sequencing	52
4.5 Electrophoresis	53
4.6 Mass Spectrometry	54
4.7 Other Technologies	55
5 Segmentation of Asia Pacific Market by Application	56
5.1 Market Overview by Application	56
5.2 Oncology	58
5.3 Infectious Diseases	59
5.4 Neurology/Psychiatry	60
5.5 Cardiovascular	62
5.6 Pain Management	63
5.7 Other Applications	64
6 Segmentation of Asia Pacific Market by End User	65
6.1 Market Overview by End User	65
6.2 Hospitals and Clinics	67
6.3 Pharmaceutical Companies	68
6.4 Research Institutes	69
7 Asia-Pacific Market 2019-2030 by Country	70
7.1 Overview of Asia-Pacific Market	70
7.2 Japan	73
7.3 China	76
7.4 Australia	78
7.5 India	80
7.6 South Korea	82
7.7 Rest of APAC Region	84
8 Competitive Landscape	86
8.1 Overview of Key Vendors	86
8.2 New Product Launch, Partnership, Investment, and M&A	90
8.3 Company Profiles	91
23andMe, Inc.	91
Abbott Laboratories	93
Admera Health, LLC	94
Agena Biosciences, Inc.	95
Astra Zeneca PLC	96
Bayer AG	97
Becton, Dickinson and Company	98
Cancer Genetics, Inc.	99
Dynamic DNA Laboratories	100
Empire Genomics LLC	101
F. Hoffmann-La Roche Ltd	102
geneOmbio Technologies Pvt Ltd.	103
Genomic Health, Inc.	104
Illumina, Inc.	105
Laboratory Corporation of America Holdings	106
Myriad Genetics Inc.	107
Oneome LLC	108
Opko Health, Inc.	109
Pathway Genomics Corporation	110
QIAGEN N.V.	111
Quest Diagnostics Incorporated	112
Teva Pharmaceuticals Industries Ltd.	113
Thermo Fisher Scientific Inc.	114
Transgenomic, Inc.	115
9 Investing in Asia Pacific Market: Risk Assessment and Management	116
9.1 Risk Evaluation of Asia Pacific Market	116
9.2 Critical Success Factors (CSFs)	119
Related Reports and Products	122
List Of Tables

Table 1.  Snapshot of Asia Pacific Pharmacogenomics Market, 2019-2030	18
Table 2. Web-based Resources of Pharmacogenomics	23
Table 3.  Main Product Trends and Market Opportunities in Asia Pacific Pharmacogenomics Market	33
Table 4. Asia Pacific Pharmacogenomics Market by Service, 2019-2030, $ mn	41
Table 5. Medicine/Gene Matching in Pharmacogenetic Testing	46
Table 6. Asia Pacific Pharmacogenomics Market by Technology, 2019-2030, $ mn	48
Table 7. Asia Pacific Pharmacogenomics Market by Application, 2019-2030, $ mn	56
Table 8. Important Drug-Gene Pairs Relevant to Neurology and Psychiatry	61
Table 9. Asia Pacific Pharmacogenomics Market by End User, 2019-2030, $ mn	65
Table 10. APAC Pharmacogenomics Market by Country, 2019-2030, $ mn	71
Table 11. Japan Pharmacogenomics Market by Service, 2019-2030, $ mn	75
Table 12. Japan Pharmacogenomics Market by Technology, 2019-2030, $ mn	75
Table 13. Japan Pharmacogenomics Market by Application, 2019-2030, $ mn	75
Table 14. China Pharmacogenomics Market by Service, 2019-2030, $ mn	77
Table 15. China Pharmacogenomics Market by Technology, 2019-2030, $ mn	77
Table 16. China Pharmacogenomics Market by Application, 2019-2030, $ mn	77
Table 17. Australia Pharmacogenomics Market by Service, 2019-2030, $ mn	79
Table 18. Australia Pharmacogenomics Market by Technology, 2019-2030, $ mn	79
Table 19. Australia Pharmacogenomics Market by Application, 2019-2030, $ mn	79
Table 20. India Pharmacogenomics Market by Service, 2019-2030, $ mn	81
Table 21. India Pharmacogenomics Market by Technology, 2019-2030, $ mn	81
Table 22. India Pharmacogenomics Market by Application, 2019-2030, $ mn	81
Table 23. South Korea Pharmacogenomics Market by Service, 2019-2030, $ mn	83
Table 24. South Korea Pharmacogenomics Market by Technology, 2019-2030, $ mn	83
Table 25. South Korea Pharmacogenomics Market by Application, 2019-2030, $ mn	83
Table 26. Pharmacogenomics Market in Rest of APAC by Country, 2019-2030, $ mn	85
Table 27. Product Approvals by Company, January 2016 – April 2019	88
Table 28. Breakdown of Asia Pacific Market by Key Vendor, 2019, %	88
Table 29. 23andMe, Inc.: Company Snapshot	91
Table 30. 23andMe, Inc.: Business Segmentation	91
Table 31. 23andMe, Inc.: Product Portfolio	92
Table 32. 23andMe, Inc.: Revenue, 2016-2018, $ mn	92
Table 33. 23andMe, Inc.: Recent Developments	92
Table 34.  Risk Evaluation for Investing in Asia Pacific Market, 2019-2030	117
Table 35. Critical Success Factors and Key Takeaways	120
List Of Figures

Figure 1. Research Method Flow Chart	11
Figure 2. Breakdown of Primary Research	13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	15
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	17
Figure 5. Asia Pacific Pharmacogenomics Market, 2019-2030, $ mn	20
Figure 6. An Overall Process of How Pharmacogenomics Functions in a Clinical Practice	22
Figure 7. Impact of COVID-19 on Business	24
Figure 8. Primary Drivers and Impact Factors of Asia Pacific Pharmacogenomics Market	26
Figure 9. World Top 10 Causes of Deaths, 2016	29
Figure 10. Primary Restraints and Impact Factors of Asia Pacific Pharmacogenomics Market	30
Figure 11. Consecutive Phases and Associated Challenges in Pharmacogenomics	32
Figure 12. Investment Opportunity Analysis	34
Figure 13. Porter’s Fiver Forces Analysis of Asia Pacific Pharmacogenomics Market	37
Figure 14. Breakdown of Asia Pacific Pharmacogenomics Market by Service, 2019-2030, % of Revenue	41
Figure 15. Asia Pacific Addressable Market Cap in 2020-2030 by Service, Value ($ mn) and Share (%)	42
Figure 16. Asia Pacific Pharmacogenomics Market: Genotyping, 2019-2030, $ mn	43
Figure 17. Asia Pacific Pharmacogenomics Market: SNP Identification, 2019-2030, $ mn	44
Figure 18. Asia Pacific Pharmacogenomics Market: Diagnostics, 2019-2030, $ mn	45
Figure 19. Asia Pacific Pharmacogenomics Market: Other Services, 2019-2030, $ mn	47
Figure 20. Breakdown of Asia Pacific Pharmacogenomics Market by Technology, 2019-2030, % of Sales Revenue	48
Figure 21. Asia Pacific Addressable Market Cap in 2020-2030 by Technology, Value ($ mn) and Share (%)	49
Figure 22. Asia Pacific Pharmacogenomics Market: Polymerase Chain Reaction (PCR), 2019-2030, $ mn	50
Figure 23. Asia Pacific Pharmacogenomics Market: Microarray, 2019-2030, $ mn	51
Figure 24. Asia Pacific Pharmacogenomics Market: Sequencing, 2019-2030, $ mn	52
Figure 25. Asia Pacific Pharmacogenomics Market: Electrophoresis, 2019-2030, $ mn	53
Figure 26. Asia Pacific Pharmacogenomics Market: Mass Spectrometry, 2019-2030, $ mn	54
Figure 27. Asia Pacific Pharmacogenomics Market: Other Technologies, 2019-2030, $ mn	55
Figure 28. Breakdown of Asia Pacific Pharmacogenomics Market by Application, 2019-2030, % of Sales Revenue	56
Figure 29. Asia Pacific Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%)	57
Figure 30. Asia Pacific Pharmacogenomics Market: Oncology, 2019-2030, $ mn	58
Figure 31. Asia Pacific Pharmacogenomics Market: Infectious Diseases, 2019-2030, $ mn	59
Figure 32. Asia Pacific Pharmacogenomics Market: Neurology/Psychiatry, 2019-2030, $ mn	60
Figure 33. Asia Pacific Pharmacogenomics Market: Cardiovascular, 2019-2030, $ mn	62
Figure 34. Asia Pacific Pharmacogenomics Market: Pain Management, 2019-2030, $ mn	63
Figure 35. Asia Pacific Pharmacogenomics Market: Other Applications, 2019-2030, $ mn	64
Figure 36. Breakdown of Asia Pacific Pharmacogenomics Market by End User, 2019-2030, % of Revenue	65
Figure 37. Asia Pacific Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%)	66
Figure 38. Asia Pacific Pharmacogenomics Market: Hospitals and Clinics, 2019-2030, $ mn	67
Figure 39. Asia Pacific Pharmacogenomics Market: Pharmaceutical Companies, 2019-2030, $ mn	68
Figure 40. Asia Pacific Pharmacogenomics Market: Research Institutes, 2019-2030, $ mn	69
Figure 41. Breakdown of APAC Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue	71
Figure 42. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)	72
Figure 43.  Pharmacogenomics Market in Japan, 2019-2030, $ mn	74
Figure 44.  Pharmacogenomics Market in China, 2019-2030, $ mn	76
Figure 45.  Pharmacogenomics Market in Australia, 2019-2030, $ mn	78
Figure 46.  Pharmacogenomics Market in India, 2019-2030, $ mn	80
Figure 47.  Pharmacogenomics Market in South Korea, 2019-2030, $ mn	82
Figure 48.  Pharmacogenomics Market in Rest of APAC, 2019-2030, $ mn	84
Figure 49. Growth Stage of Asia Pacific Pharmacogenomics Industry over the Forecast Period	86

Key Players (this may not be a complete list and extra companies can be added upon request): 
3M Health Care Limited 
Adherium Limited 
Amiko Digital Health Limited 
AsthmaMD 
AstraZeneca plc 
Boehringer Ingelheim International GmbH 
Capsule Technologies, Inc. 
Cohero Health 
GlaxoSmithKline plc 
Kaia Health Software GmbH 
Medical International Research (MIR) 
Novartis AG 
NuvoAir 
Reciprocal Labs (Propeller Health) 
Sensiron AG 
Tactio Health 
Teva Pharmaceuticals Industries Ltd.